Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00557505 | A Study Of PF-03732010 In Patients With Advanced Solid Tumors | PHASE1 | COMPLETED | 43 | — | — | Dec 1, 2007 | Feb 1, 2011 | Mar 26, 2012 | 3 | United States, Australia +1 |
| Arm | Type | Description |
|---|---|---|
| PF-03732010 | EXPERIMENTAL | Single Arm study |
| Name | Type | Description |
|---|---|---|
| PF-03732010 | DRUG | IV infusion. Escalating dose levels, starting at 0.5 mg/kg to Maximum Tolerated Dose. Cycle length of 4 weeks for first cycle, and 2 weekly for subsequently cycles was originally explored, yet based on emerging PK data the Cycle 1 duration is 2 weeks and then weekly. Number of Cycles: Until Progression or unacceptable toxicity develops. |
Inclusion Criteria: * Advanced solid tumors refractory to (or intolerant of) established therapy known to provide clinical benefit, or for which there is no standard therapy * Age \>= 18 years of age * Adequate bone marrow function as defined by: absolute neutrophil count (ANC) ≥1500/uL, hemoglobin...